Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Reports Fiscal 2012 Third Quarter Financial Results
Arrowhead Reports Fiscal 2012 Third Quarter Financial Results PASADENA, Calif. — August 13, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced financial results for its fiscal 2012 third quarter ended June 30, 2012.
View HTML
Toggle Summary Arrowhead Raises $6.2 Million through Registered Direct Offering of Common Stock and Warrants
Arrowhead Raises $6.2 Million through Registered Direct Offering of Common Stock and Warrants Pasadena, CA — August 13, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has entered into a securities purchase agreement with institutional and individual investors to raise
View HTML
Toggle Summary Arrowhead Research to Present at 2012 Wedbush PacGrow Life Sciences Management Access Conference
Arrowhead Research to Present at 2012 Wedbush PacGrow Life Sciences Management Access Conference PASADENA, Calif. — August 9, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that its President and Chief Executive Officer, Dr.
View HTML
Toggle Summary Arrowhead to Report Fiscal 2012 Third Quarter Financial Results
Conference Call Scheduled for Monday, August 13, 2012
View HTML
Toggle Summary Arrowhead Announces Dosing of First Patient with Anti-Obesity Treatment Adipotide® in a Phase 1 Clinical Trial
Arrowhead Announces Dosing of First Patient with Anti-Obesity Treatment Adipotide® in a Phase 1 Clinical Trial PASADENA, Calif. — July 11, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that the first patient has been dosed in a Phase 1
View HTML
Toggle Summary Arrowhead Announces New Study Demonstrating Rapid Improvement in Pro-Diabetic Metabolic Markers with Anti-Obesity Drug Candidate, Adipotide®
Arrowhead Announces New Study Demonstrating Rapid Improvement in Pro-Diabetic Metabolic Markers with Anti-Obesity Drug Candidate, Adipotide® PASADENA, Calif. — June 26, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR) , a targeted therapeutics company, today announced the publication of data
View HTML
Toggle Summary Arrowhead Research Advances ARC-520 into IND-Enabling Studies for the Treatment of Hepatitis B and Provides Guidance on Development Timeline
Arrowhead Research Advances ARC-520 into IND-Enabling Studies for the Treatment of Hepatitis B and Provides Guidance on Development Timeline PASADENA, Calif. — June 6, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR) , a targeted therapeutics company, today announced that its hepatitis B virus
View HTML
Toggle Summary Arrowhead Presents Data on DPC System at TIDES 2012
Delivery polymer provides dramatic reduction in effective dose of Cholesterol-conjugated siRNA
View HTML
Toggle Summary Arrowhead Presents Data on DPC System and Hepatitis B Program at CLINAM 2012
Preclinical studies show substantial reduction of serum HBsAg, HBV DNA and dramatically decreased HBV RNA and DNA in liver
View HTML
Toggle Summary Arrowhead Reports Fiscal 2012 Second Quarter Financial Results
Arrowhead Reports Fiscal 2012 Second Quarter Financial Results PASADENA, Calif. — May 8, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, today announced financial results for its fiscal 2012 second quarter ended
View HTML